The metastatic brain lesion harbored morphologic, immunohistochemical, and methylation profile supportive of a primary CNS phenotype with loss of the trimethylated lysine 27 residue of histone 3 while maintaining INI1 loss and a specific gene fusion shared with the patient’s tumor prior to initiation of tazemetostat therapy. This evidence concerns the gene SMARCB1 and neoplasm.